Regulatory role of lncH19 in RAC1 alternative splicing: implication for RAC1B expression in colorectal cancer.


Journal

Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647

Informations de publication

Date de publication:
05 Aug 2024
Historique:
received: 19 04 2024
accepted: 26 07 2024
medline: 5 8 2024
pubmed: 5 8 2024
entrez: 4 8 2024
Statut: epublish

Résumé

Aberrant alternative splicing events play a critical role in cancer biology, contributing to tumor invasion, metastasis, epithelial-mesenchymal transition, and drug resistance. Recent studies have shown that alternative splicing is a key feature for transcriptomic variations in colorectal cancer, which ranks third among malignant tumors worldwide in both incidence and mortality. Long non-coding RNAs can modulate this process by acting as trans-regulatory agents, recruiting splicing factors, or driving them to specific targeted genes. LncH19 is a lncRNA dis-regulated in several tumor types and, in colorectal cancer, it plays a critical role in tumor onset, progression, and metastasis. In this paper, we found, that in colorectal cancer cells, the long non-coding RNA H19 can bind immature RNAs and splicing factors as hnRNPM and RBFOX2. Through bioinformatic analysis, we identified 57 transcripts associated with lncH19 and containing binding sites for both splicing factors, hnRNPM, and RBFOX2. Among these transcripts, we identified the mRNA of the GTPase-RAC1, whose alternatively spliced isoform, RAC1B, has been ascribed several roles in the malignant transformation. We confirmed, in vitro, the binding of the splicing factors to both the transcripts RAC1 and lncH19. Loss and gain of expression experiments in two colorectal cancer cell lines (SW620 and HCT116) demonstrated that lncH19 is required for RAC1B expression and, through RAC1B, it induces c-Myc and Cyclin-D increase. In vivo, investigation from biopsies of colorectal cancer patients showed higher levels of all the explored genes (lncH19, RAC1B, c-Myc and Cyclin-D) concerning the healthy counterpart, thus supporting our in vitro model. In addition, we identified a positive correlation between lncH19 and RAC1B in colorectal cancer patients. Finally, we demonstrated that lncH19, as a shuttle, drives the splicing factors RBFOX2 and hnRNPM to RAC1 allowing exon retention and RAC1B expression. The data shown in this paper represent the first evidence of a new mechanism of action by which lncH19 carries out its functions as an oncogene by prompting colorectal cancer through the modulation of alternative splicing.

Identifiants

pubmed: 39098911
doi: 10.1186/s13046-024-03139-z
pii: 10.1186/s13046-024-03139-z
doi:

Substances chimiques

RNA, Long Noncoding 0
rac1 GTP-Binding Protein EC 3.6.5.2
RNA Splicing Factors 0
RAC1 protein, human 0
Heterogeneous-Nuclear Ribonucleoprotein Group M 0
RBFOX2 protein, human 0
HNRNPM protein, human 0
Repressor Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

217

Subventions

Organisme : Fondazione AIRC
ID : 19982

Informations de copyright

© 2024. The Author(s).

Références

Wu S, et al. Emerging roles of noncoding RNAs in human cancers. Discov Oncol. 2023;14(1):128.
doi: 10.1007/s12672-023-00728-w pubmed: 37439905 pmcid: 10344860
Liao J, et al. Long noncoding RNA (lncRNA) H19: an essential developmental regulator with expanding roles in cancer, stem cell differentiation, and metabolic diseases. Genes Dis. 2023;10(4):1351–66.
doi: 10.1016/j.gendis.2023.02.008 pubmed: 37397543 pmcid: 10311118
Yang J, et al. LncRNA H19: a novel oncogene in multiple cancers. Int J Biol Sci. 2021;17(12):3188–208.
doi: 10.7150/ijbs.62573 pubmed: 34421359 pmcid: 8375239
Ghafouri-Fard S, Esmaeili M, Taheri M. H19 lncRNA: roles in tumorigenesis. Biomed Pharmacother. 2020;123:109774.
doi: 10.1016/j.biopha.2019.109774 pubmed: 31855739
Escobar-Hoyos L, Knorr K, Abdel-Wahab O. Aberrant RNA splicing in Cancer. Annu Rev Cancer Biol. 2019;3(1):167–85.
doi: 10.1146/annurev-cancerbio-030617-050407 pubmed: 32864546
Zong Z, et al. Genome-wide profiling of Prognostic Alternative Splicing signature in Colorectal Cancer. Front Oncol. 2018;8:537.
doi: 10.3389/fonc.2018.00537 pubmed: 30524964 pmcid: 6262947
Xiong Y, et al. Profiles of alternative splicing in colorectal cancer and their clinical significance: a study based on large-scale sequencing data. EBioMedicine. 2018;36:183–95.
doi: 10.1016/j.ebiom.2018.09.021 pubmed: 30243491 pmcid: 6197784
Carazo F, et al. Integration of CLIP experiments of RNA-binding proteins: a novel approach to predict context-dependent splicing factors from transcriptomic data. BMC Genomics. 2019;20(1):521.
doi: 10.1186/s12864-019-5900-1 pubmed: 31238884 pmcid: 6592009
Venables JP, et al. RBFOX2 is an important regulator of mesenchymal tissue-specific splicing in both normal and cancer tissues. Mol Cell Biol. 2013;33(2):396–405.
doi: 10.1128/MCB.01174-12 pubmed: 23149937 pmcid: 3554129
Braeutigam C, et al. The RNA-binding protein Rbfox2: an essential regulator of EMT-driven alternative splicing and a mediator of cellular invasion. Oncogene. 2014;33(9):1082–92.
doi: 10.1038/onc.2013.50 pubmed: 23435423
Brosseau JP, et al. Tumor microenvironment-associated modifications of alternative splicing. RNA. 2014;20(2):189–201.
doi: 10.1261/rna.042168.113 pubmed: 24335142 pmcid: 3895271
Damianov A, et al. Rbfox proteins regulate splicing as part of a large Multiprotein Complex LASR. Cell. 2016;165(3):606–19.
doi: 10.1016/j.cell.2016.03.040 pubmed: 27104978 pmcid: 4841943
Zhou D, et al. RBFOX2 alters splicing outcome in distinct binding modes with multiple protein partners. Nucleic Acids Res. 2021;49(14):8370–83.
doi: 10.1093/nar/gkab595 pubmed: 34244793 pmcid: 8373071
Mochizuki Y, et al. Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer. Int J Cancer. 2021;149(10):1787–800.
doi: 10.1002/ijc.33758 pubmed: 34346508
Ouyang J, et al. Long non-coding RNAs are involved in alternative splicing and promote cancer progression. Br J Cancer. 2022;126(8):1113–24.
doi: 10.1038/s41416-021-01600-w pubmed: 34750493
Amirkhah R et al. The intricate interplay between epigenetic events, alternative splicing and noncoding RNA deregulation in Colorectal Cancer. Cells, 2019. 8(8).
Melzer C et al. RAC1B: a rho GTPase with versatile functions in Malignant Transformation and Tumor Progression. Cells, 2019. 8(1).
Gudino V, et al. RAC1B modulates intestinal tumourigenesis via modulation of WNT and EGFR signalling pathways. Nat Commun. 2021;12(1):2335.
doi: 10.1038/s41467-021-22531-3 pubmed: 33879799 pmcid: 8058071
Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads 2011, 2011. 17(1): p. 3.
Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21.
doi: 10.1093/bioinformatics/bts635 pubmed: 23104886
Gaspar JM. Improved peak-calling with MACS2 bioRxiv, 2018: p. 496521.
Fukunaga T, Hamada M. RIblast: an ultrafast RNA-RNA interaction prediction system based on a seed-and-extension approach. Bioinformatics. 2017;33(17):2666–74.
doi: 10.1093/bioinformatics/btx287 pubmed: 28459942 pmcid: 5860064
Armaos A et al. catRAPID omics v2.0: going deeper and wider in the prediction of protein-RNA interactions Nucleic Acids Res, 2021. 49(W1): pp. W72-W79.
Van Nostrand EL, et al. Principles of RNA processing from analysis of enhanced CLIP maps for 150 RNA binding proteins. Genome Biol. 2020;21(1):90.
doi: 10.1186/s13059-020-01982-9 pubmed: 32252787 pmcid: 7137325
Crowley LC, Chojnowski G, Waterhouse NJ. Measuring the DNA content of cells in apoptosis and at different cell-cycle stages by Propidium Iodide Staining and Flow Cytometry. Cold Spring Harb Protoc; 2016. 2016(10).
Liu Y, et al. Noncoding RNAs regulate alternative splicing in Cancer. J Exp Clin Cancer Res. 2021;40(1):11.
doi: 10.1186/s13046-020-01798-2 pubmed: 33407694 pmcid: 7789004
Romero-Barrios N, et al. Splicing regulation by long noncoding RNAs. Nucleic Acids Res. 2018;46(5):2169–84.
doi: 10.1093/nar/gky095 pubmed: 29425321 pmcid: 5861421
Aparicio LA, et al. Posttranscriptional regulation by RNA-binding proteins during epithelial-to-mesenchymal transition. Cell Mol Life Sci. 2013;70(23):4463–77.
doi: 10.1007/s00018-013-1379-0 pubmed: 23715860 pmcid: 3827902
Maurin M, et al. RBFOX2 deregulation promotes pancreatic cancer progression and metastasis through alternative splicing. Nat Commun. 2023;14(1):8444.
doi: 10.1038/s41467-023-44126-w pubmed: 38114498 pmcid: 10730836
Pethe VV, Charames GS, Bapat B. Rac1b recruits dishevelled and beta-catenin to wnt target gene promoters independent of Wnt3A stimulation. Int J Oncol. 2011;39(4):805–10.
pubmed: 21667018
Esufali S, et al. Activation of tumor-specific splice variant Rac1b by dishevelled promotes canonical wnt signaling and decreased adhesion of colorectal cancer cells. Cancer Res. 2007;67(6):2469–79.
doi: 10.1158/0008-5472.CAN-06-2843 pubmed: 17363564
Shutes A, et al. Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of rac family small GTPases. J Biol Chem. 2007;282(49):35666–78.
doi: 10.1074/jbc.M703571200 pubmed: 17932039
Tripathi V, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010;39(6):925–38.
doi: 10.1016/j.molcel.2010.08.011 pubmed: 20797886 pmcid: 4158944
Meng LD, et al. Linc01232 promotes the metastasis of pancreatic cancer by suppressing the ubiquitin-mediated degradation of HNRNPA2B1 and activating the a-raf-induced MAPK/ERK signaling pathway. Cancer Lett. 2020;494:107–20.
doi: 10.1016/j.canlet.2020.08.001 pubmed: 32814086
Goncalves V, Matos P, Jordan P. Antagonistic SR proteins regulate alternative splicing of tumor-related Rac1b downstream of the PI3-kinase and wnt pathways. Hum Mol Genet. 2009;18(19):3696–707.
doi: 10.1093/hmg/ddp317 pubmed: 19602482
Ding D, et al. LncRNA H19/miR-29b-3p/PGRN Axis promoted epithelial-mesenchymal transition of Colorectal Cancer cells by acting on wnt signaling. Mol Cells. 2018;41(5):423–35.
pubmed: 29754471 pmcid: 5974619
Saieva L et al. Hypoxia-Induced mir-675-5p supports beta-catenin Nuclear localization by regulating GSK3-beta activity in Colorectal Cancer Cell lines. Int J Mol Sci, 2020. 21(11).
Ohtsuka M, et al. H19 noncoding RNA, an independent prognostic factor, regulates essential Rb-E2F and CDK8-beta-catenin signaling in Colorectal Cancer. EBioMedicine. 2016;13:113–24.
doi: 10.1016/j.ebiom.2016.10.026 pubmed: 27789274 pmcid: 5264449

Auteurs

Aurora Cordaro (A)

Department of Biomedicine Neuroscience and Advanced Diagnostic, University of Palermo, Palermo, Italy.

Maria Magdalena Barreca (MM)

Department of Biomedicine Neuroscience and Advanced Diagnostic, University of Palermo, Palermo, Italy.

Chiara Zichittella (C)

Department of Biomedicine Neuroscience and Advanced Diagnostic, University of Palermo, Palermo, Italy.

Marco Loria (M)

Department of Biomedicine Neuroscience and Advanced Diagnostic, University of Palermo, Palermo, Italy.

Denise Anello (D)

Department of Biomedicine Neuroscience and Advanced Diagnostic, University of Palermo, Palermo, Italy.

Goffredo Arena (G)

McGill University Health Centre, Montréal, Canada.
Fondazione Istituto G. Giglio di Cefalù, Cefalù, Italy.

Nicolina Sciaraffa (N)

Advanced Data Analysis Group, Ri.MED Foundation, Palermo, Italy.

Claudia Coronnello (C)

Advanced Data Analysis Group, Ri.MED Foundation, Palermo, Italy.

Giuseppe Pizzolanti (G)

Dipartimento di Promozione della Salute, Materno-Infantile, di Medicina Interna e Specialistica di Eccellenza "G. D'Alessandro", PROMISE, University of Palermo, Palermo, 90127, Italy.
AteN Center-Advanced Technologies Network Center, University of Palermo, Palermo, 90128, Italy.

Riccardo Alessandro (R)

Department of Biomedicine Neuroscience and Advanced Diagnostic, University of Palermo, Palermo, Italy.
Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), Palermo, Italy.

Alice Conigliaro (A)

Department of Biomedicine Neuroscience and Advanced Diagnostic, University of Palermo, Palermo, Italy. alice.conigliaro@unipa.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH